Zentalis
ZNTL
Zentalis (ZNTL) news
Recent news
Zentalis Pharmaceuticals, Inc.: Leerink Partners assumes coverage with outperform vs market perform rating; target price $8 vs $4
Leerink Partners has initiated coverage of Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) with an "outperform" rating, surpassing the previous "market perform" assessment, and has set a target price of $8 per share, up from the prior $4. The firm's updated stance reflects a positive outlook on the…
AInvest Wire · Oct 5, 2026Zentalis Pharmaceuticals, Inc.: William Blair initiates coverage with outperform rating
AInvest Wire · Sep 16, 2026Zentalis Pharmaceuticals prices 23M shares offering at $3.50 each
AInvest Wire · Aug 14, 2026Zentalis Pharma said to seek $75M in share sale at $3.50 each
AInvest Wire · Aug 13, 2026Zentalis Pharmaceuticals Q2 EPS USD -0.59
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.